1 / 12

The EMERALD Trial Diabetic Substudy

The EMERALD Trial Diabetic Substudy. EMERALD Diabetic Analysis.

jaime-gilmore
Download Presentation

The EMERALD Trial Diabetic Substudy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The EMERALD TrialDiabetic Substudy

  2. EMERALD Diabetic Analysis To compare myocardial perfusion and infarct sizes in diabetic and non-diabetic patients undergoing primary percutaneous coronary intervention (PCI) in the EMERALD (Enhanced Myocardial Efficacy and Removal by Aspiration of Liberated Debris) trial for ST-segment elevation myocardial infarction Objective Marso et al. Am J Cardiol 2007;100:206-210

  3. EMERALD Diabetic AnalysisStudy Design • Inclusion • Age>18 years • Acute myocardial infarction >6 hours • ST-elevation ≥2mm in ≥contiguous leads, LBBB • Exclusion • Multivessel PCI • Unprotected left main PCI • Expected CABG within 30 days Secondary Outcome Final TIMI flow Myocardial blush Angiographic complications Marso et al. Am J Cardiol 2007;100:206-210

  4. EMERALD Diabetic AnalysisBaseline Characteristics Marso et al. Am J Cardiol 2007;100:206-210

  5. EMERALD Diabetic AnalysisAngiographic & Procedural Characteristics Marso et al. Am J Cardiol 2007;100:206-210

  6. EMERALD Diabetic AnalysisAngiographic & Procedural Characteristics Marso et al. Am J Cardiol 2007;100:206-210

  7. EMERALD Diabetic AnalysisPrimary Outcomes P=1.0 P=0.005 P=0.002 P<0.0001 Marso et al. Am J Cardiol 2007;100:206-210

  8. EMERALD Diabetic AnalysisPrimary Outcomes P=0.005 Marso et al. Am J Cardiol 2007;100:206-210

  9. EMERALD Diabetic AnalysisSecondary Outcomes P<0.001 P=0.04 P=0.002 P=0.02 Marso et al. Am J Cardiol 2007;100:206-210

  10. EMERALD Diabetic AnalysisMultivariable Predictors of Complete ST-Resolution Marso et al. Am J Cardiol 2007;100:206-210

  11. EMERALD Diabetic AnalysisMultivariable Predictors of 6-Month Mortality Marso et al. Am J Cardiol 2007;100:206-210

  12. EMERALD Diabetic Analysis Conclusions • Myocardial reperfusion is decreased as measured by incomplete ST-resolution and myocardial blush grade • Lower rates of reperfusion are associated with greater infarct sizes compared to non-diabetic patients • There is no additional benefit of using distal embolic protection, similar to non-diabetic patients In diabetic patients undergoing percutaneous coronary intervention: Marso et al. Am J Cardiol 2007;100:206-210

More Related